Maintenance. We are currently updating the site. Please check back shortly
Members login
  • TrustLaw
  • Members Portal
Subscribe Donate

J&J recalls nearly 2 mln blood glucose meters worldwide

Source: Thomson Reuters Foundation - Mon, 25 Mar 2013 19:55 GMT
Author: Reuters
Tweet Recommend Google + LinkedIn Email Print
Leave us a comment

(Corrects headline, first paragraph to nearly 2 million, from more than)

* Meters fail to warn of extremely high glucose levels

* Health regulators, patients notified of recall

* OneTouch Verio IQ, Verio Pro and Verio Pro+ affected

March 25 (Reuters) - Johnson & Johnson is recalling and replacing nearly 2 million meters used to measure blood glucose levels in diabetics due to a failure to operate properly at extremely high glucose readings, the company's LifeScan unit said on Monday.

In the United States, about 90,000 OneTouch Verio IQ meters are affected out of some 1.2 million units of that model being recalled worldwide, the company said.

At extremely high glucose readings of 1024 mg/dl and above, the units have failed to provide a warning of dangerously high blood sugar and will shut off, potentially delaying proper treatment, the company said.

LifeScan said it has notified the U.S. Food and Drug Administration and other health regulators of the voluntary recall, as well as registered users and healthcare professionals.

In addition to the Verio IQ model, J&J is also recalling about 670,000 of its OneTouch Verio Pro meters in Europe and 4,900 of its hospital-based OneTouch Verio Pro+ meters in the Middle East, Europe and the Asia/Pacific region.

No patient injuries have been reported in the United States related to the malfunction, the company said. LifeScan said there was one report of a serious adverse event outside the United States, but a link to the malfunctioning glucose meter had not been determined.

"We regret the inconvenience these actions may cause. However, we will always err on the side of caution and make a decision that is in the best interest of our patients," Michael Pfeifer, LifeScan's chief medical officer, said in a statement.

The company said its OneTouch Ultra model was not affected by the recall.

It said patients could continue to use the Verio IQ model until replacements arrive as long as they are aware that if the unit shuts down it could be indicative of dangerously high glucose levels. (Reporting by Bill Berkrot; editing by John Wallace)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of the Thomson Reuters Foundation. For more information see our Acceptable Use Policy.

comments powered by Disqus
Most Popular
LATEST SLIDESHOW

Latest slideshow

See allSee all
FEATURED JOBS
Featured jobs